June has been one roller coaster ride for cannabis stocks. First, the FDA reported that CBD be treated like a drug causing cannabis …
GW Pharmaceuticals (GWPH) has recently bounced after a solid earnings report. It also announced its phase-3 trial concerning its Epidiolex oral medicine, received …
The cannabis market has the potential to be extremely lucrative for investors. For example, shares of cannabis grower Hexo (HEXO) are now up …
By Genia Turanova For centuries, humans relied on plant-derived medicines, using — based on countless experiments and astute observation — a wide range …
GW Pharma (GWPH) has the distinction of having the first cannabis-derived prescription drug that was approved by the FDA: Epidiolex. This drug is …
J.P Morgan analyst Cory Kasimov initiates coverage for medical cannabis company GW Pharmaceuticals (GWPH), calling it a “clear leader” in the field of cannabinoid …
This morning, GW Pharmaceuticals (GWPH) announced that EPIDIOLEX (cannabidiol) oral solution has been transferred to Schedule V, the lowest restriction classification, by the U.S.
There’s a new FDA-approved cannabis-based medicine on the scene. Today, the U.
Cowen’s Phil Nadeau joins the bullish conversation buzzing about GWPh’s cannabis-based epilepsy drug after a unanimous nod from the FDA AdCom panel.
